Evidence map›Paper›PMID 27806994›Full record

ReviewClinical microbiology reviews2017

Human Parvoviruses.

Jianming Qiu, Maria Söderlund-Venermo, Neal S Young

Abstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 226 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
226citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

226 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. A decision-making process to guide the potential application of a hepatitis A virus and parvovirus B19 nucleic acid test for qualifying plasma for fractionation.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026
    Article
  14. Article
  15. Article
  16. Human herpesvirus type 7 and bone marrow disorders: a new association to consider in relation with a case report.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

166 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jianming QiuDepartment of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, USA jqiu@kumc.edu.
Maria Söderlund-VenermoDepartment of Virology, University of Helsinki, Helsinki, Finland.
Neal S YoungHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Novel Approaches for the Control of Microbial PathogensP30GM103326 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LUTKENHAUS, JOSEPH F · 2012 to 2016
$5.3M
Post-Transcriptional Regulation of Parvovirus Capsid Gene ExpressionR01AI070723 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING · 2007 to 2017
$3.3M
Study of Human Bocavirus Gene Expression for Development of a Parvoviral VectorR21AI112803 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING · 2015 to 2016
$429k
Study of Human Bocavirus Infection in Human Airway EpitheliaR21AI105543 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING · 2014 to 2015
$428k
NIAID NIH HHS R01 AI070723NIAID NIH HHS R21 AI105543NIAID NIH HHS R21 AI112803NIGMS NIH HHS P30 GM103326
6 · The paper itself

Abstract

Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.

Indexed as

Gene Expression Regulation, ViralGenome, ViralHuman bocavirusHumansParvoviridae InfectionsParvovirus B19, HumanPrevalenceViral VaccinesViral VaccinesB19 virushuman bocavirusparvovirus

Identifiers

PMID27806994
PMCPMC5217800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.